The study, published in the open-access journal Stress Biology, focused on a commercially available fungicide formulation containing two beneficial fungal strains, Trichoderma asperellum ICC012 and Trichoderma gamsii ICC080. Trichoderma species are filamentous fungi famous among plant scientists for their mycoparasitic and antagonistic activities against a wide range of plant pathogens, and they are already registered and widely used as microbial fungicides. What has remained poorly understood, however, is precisely what happens at the level of gene expression inside host roots when these beneficial fungi are deployed ahead of a pathogen attack. The new research set out to close that gap by combining classical disease screening with high-throughput RNA sequencing and an advanced statistical framework known as Weighted Gene Co-expression Network Analysis, or WGCNA.

The phenotypic results were striking. In greenhouse trials using the Greek melon variety ‘Xrisi-kefali’, seedlings inoculated with FOM alone developed the full suite of Fusarium wilt symptoms, and by the end of the observation period the disease incidence had reached one hundred percent, with roughly 79 percent of leaves lost to defoliation. Seedlings pre-treated with the Trichoderma formulation before pathogen inoculation told a very different story. Disease incidence in this group was limited to about 40 percent, defoliation dropped to approximately 28 percent, and weekly disease index assessments over four consecutive weeks showed significantly lower severity compared with pathogen-only plants. Beyond disease suppression, the treated seedlings also grew better, showing greater shoot height, thicker stems, and more internodes, consistent with the well-documented growth-promoting activity of Trichoderma in the rhizosphere, which is thought to involve improved nutrient availability, mineral solubilization, iron chelation, and the modulation of hormonal signaling pathways.

To understand the molecular machinery behind this protection, the researchers sequenced the transcriptomes of melon roots collected at one, two, and three days after pathogen inoculation, comparing three treatments: plants treated with Trichoderma and then challenged with FOM, plants challenged with the pathogen alone, and untreated healthy controls. The sequencing effort generated approximately 944 million clean reads, averaging around 34 million per sample, with more than 88 percent mapping successfully to the melon reference genome. After stringent filtering, the team identified a non-redundant set of 9254 differentially expressed genes across all comparisons. Notably, the highest number of upregulated genes appeared in Trichoderma-pretreated, pathogen-challenged roots at the first and third days after inoculation, suggesting that the beneficial fungi trigger a time-dependent surge of defensive gene activity that pathogen infection alone does not produce.

The centerpiece of the study was the network analysis. Using WGCNA, the researchers grouped the 9254 genes into co-expression modules and eventually refined them into fourteen modules, four of which emerged as decisively correlated with the treatments. Two modules, dubbed midnightblue and cyan, were most strongly associated with pathogen infection alone at two and three days after inoculation, respectively. Two others, the blue and green modules, were tightly linked to the Trichoderma-pretreated plants at the first and third days. This separation proved conceptually important: the modules tied to pathogen infection alone reflected a stressed, pathogen-driven transcriptional state, while the modules tied to the combined treatment captured the active, Trichoderma-primed defense machinery that appears to establish resistance before substantial pathogen ingress.

Within the blue module, which represents the early Trichoderma-induced response, the researchers found a remarkable concentration of defense-related hub genes, the highly connected nodes that act as central regulators of the network. Four transcription factor families stood out: NAC domain-containing protein 2, the dehydration-responsive element-binding protein DREB1A, trihelix transcription factor GT-3b, and a heat stress transcription factor. These families are known orchestrators of plant immunity in other crops; a trihelix GT-3b gene has been linked to defense against Fusarium graminearum in maize, a pathogen-induced NAC factor modulates rust resistance in barley, and DREB1A overexpression enhances biotic stress tolerance in transgenic potato. Alongside these regulators, the module contained a gene encoding caffeoylshikimate esterase, or CSE, which participates in lignin biosynthesis, a branch of the phenylpropanoid pathway that plants use to reinforce cell walls and produce antimicrobial phytoalexins against fungal invaders. KEGG pathway enrichment confirmed the module’s defensive character, highlighting phenylpropanoid biosynthesis, the MAPK signaling cascade, and plant-pathogen interaction pathways.

The blue module also harbored genes encoding a chitin receptor kinase called LYK5, which works with CERK1 to detect fungal cell wall fragments and launch immune signaling, a phloem protein 2 involved in phloem-based defense, a nerolidol synthase-like gene producing volatile defense signals, and a subtilisin-like protease implicated in immune responses. The green module, correlated with the later Trichoderma-induced response, contributed its own arsenal: a two-component response regulator ARR14-like gene involved in hormone crosstalk, Kunitz trypsin inhibitor and miraculin-like proteins with documented antifungal activity, a MYB27 transcription factor, translation-related factors, and even an aquaporin that may influence defensive signaling. Together, these findings sketch a coherent picture of Trichoderma priming the melon root to mount a faster, stronger, and more coordinated defense than it could achieve on its own.

The dual nature of the protection became even clearer when the researchers examined the pathogen’s own transcripts within the same sequencing data. Across all three time points, FOM gene expression was consistently and dramatically suppressed in the presence of the Trichoderma formulation, often approaching near-zero levels. The repressed genes included multiple ribosomal proteins, pointing to a collapse in the pathogen’s protein synthesis capacity, as well as key metabolic enzymes such as ATP synthase, malate dehydrogenase, and cytochrome c peroxidase, indicating disruption of respiration and energy production. Most tellingly, the virulence arsenal itself was silenced: genes encoding xyloglucanases, pectate lyases, endoglucanases, and exoglucanases, the carbohydrate-degrading enzymes FOM needs to pierce plant cell walls, were markedly reduced, particularly at later time points. While the authors note that formal differential expression analysis would be needed to statistically confirm these patterns, the profiles strongly suggest that Trichoderma attacks the pathogen on two fronts simultaneously, starving it at a fundamental physiological level while arming the plant against it.

Several intriguing regulatory players emerged from the pathogen-associated modules as well. The midnightblue module’s hub genes were predominantly ribosomal RNA genes, upregulated after two days of FOM infection and inverted under Trichoderma pretreatment, hinting at a pathogen-driven reprogramming of the host’s translational machinery that the beneficial fungi can counteract. The cyan module contained upregulated long non-coding RNAs, increasingly recognized as key modulators of plant immunity through their effects on reactive oxygen species, calcium signaling, and transcription factor regulation, plus two uncharacterized genes homologous to retrotransposon proteins, suggesting that transposable elements may participate in the stress response. A pyridoxal kinase gene involved in vitamin B6 biosynthesis, an essential antioxidant in stress responses, was also highly expressed in this module.

The authors are careful to frame their findings within both the promise and the caveats of biological control. The experimental design mirrored real-world practice, applying Trichoderma preventively so it can establish in the rhizosphere before pathogen challenge, and the priming-based mechanism of induced resistance depends on that prior colonization. They also acknowledge that microbial biocontrol agents can reshape soil fungal communities, sometimes reducing fungal diversity or shifting competitive equilibria in ways that depend on soil type and inoculant persistence, a knowledge gap that matters for durable, biodiversity-conscious disease management. Still, the study delivers a molecular roadmap that could inform targeted breeding strategies and refined industrial formulations. By pinpointing specific hub genes and pathways, from CSE-driven lignin reinforcement to NAC and DREB transcriptional cascades, the work transforms Trichoderma biocontrol from an empirical black box into a mechanistically understood, engineerable system for protecting one of the world’s favorite fruits.

Subject of Research: Transcriptomic mechanisms of Trichoderma-mediated biological control of Fusarium wilt in melon roots

Article Title: Transcriptomic insights into the biocontrol mechanism of Trichoderma spp. against Fusarium wilt in melon

Article References: Aci, M. M., Tsalgatidou, P. C., Krommydas, K., Boutsika, A., Delis, C., Pavli, O. I., Schena, L., & Zambounis, A. (2026). Transcriptomic insights into the biocontrol mechanism of Trichoderma spp. against Fusarium wilt in melon. Stress Biology, 6(1), Article 44. https://doi.org/10.1007/s44154-026-00315-3

Image Credits: AI Generated

DOI: 10.1007/s44154-026-00315-3

Keywords: Trichoderma, Fusarium wilt, melon, biocontrol, transcriptomics, RNA-seq, WGCNA, plant immunity, hub genes, phenylpropanoid biosynthesis, MAPK signaling, sustainable agriculture

The clinical backdrop to the work is well established. Epidemiological studies have repeatedly shown that patients with Parkinson’s disease face a strikingly elevated risk of osteoporosis and osteoporotic fractures, a burden that exceeds what can be explained by poor mobility, falls, or age alone. Meta-analyses cited by the researchers indicate high rates of osteoporotic fracture in Parkinson’s disease, and cross-sectional clinical work has associated biomarkers such as serum uric acid with reduced bone mineral density in affected patients. Yet the molecular mechanisms that bind neurodegeneration to bone loss have remained murky. The Henan University team set out to interrogate that relationship experimentally, asking whether a single genetic factor—absence of ACE2—could simultaneously perturb dopaminergic neuron survival in the brain and bone homeostasis in the skeleton.

To do so, the researchers used a well-characterized mouse model of parkinsonism in which the neurotoxin MPTP, or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, selectively destroys dopamine-producing neurons in the substantia nigra. Crucially, they crossed this challenge with mice lacking a functional ACE2 gene—specifically Ace2-null males, designated Ace2−/y—because ACE2 sits at the center of the protective arm of the renin-angiotensin system, converting angiotensin II into angiotensin-(1–7), a peptide with documented anti-inflammatory and neuroprotective actions. Previous studies from other groups and from the same team had shown that ACE2 activation mitigates behavioral deficits and neuroinflammation in chemically induced Parkinson’s models, and that the ACE2/Ang-(1–7)/Mas cascade strengthens bone structure and metabolism. The new study asked what happens when this protective factor is removed entirely under parkinsonian stress.

Behavioral testing revealed a clear aggravating effect. MPTP exposure significantly worsened motor dysfunction and depression-like behaviors in the mice, and the combination of MPTP toxicity with ACE2 deficiency produced a particularly severe pathological picture in the brain. Immunohistochemistry, Western blotting, and histopathological staining showed reduced activity of dopaminergic neurons and heightened microglial activation—the inflammatory response of the brain’s resident immune cells. At the molecular level, the researchers measured elevated levels of total α-synuclein, the misfolding-prone protein that defines Parkinson’s pathology, alongside increased abundance of Caspase-3 and Bax, two canonical executioners of programmed cell death. Together, these markers indicate that ACE2 loss intensifies both the protein aggregation burden and the apoptotic pressure on vulnerable neurons.

The bone findings were equally striking, and notably they emerged in parallel rather than secondarily. In the skeletal tissue of the Ace2-deficient mice, the team documented reduced abundance of total Wnt ligands, β-catenin, bone morphogenetic proteins (BMP), and insulin-like growth factor 1 (IGF-1), along with diminished phosphorylation ratios of the downstream kinases that transmit these signals. This matters because each of these cascades is a cornerstone of bone formation: Wnt/β-catenin signaling drives osteoblast differentiation and bone accrual, BMPs are potent inducers of bone formation used clinically in spine fusion and fracture repair, and IGF-1 couples muscle and bone metabolism through mTOR-dependent pathways. The researchers are careful to note that the parallel reduction of these signaling proteins suggests potential perturbation of the cascades rather than definitive proof of pathway failure, a distinction that reflects appropriate scientific caution.

In the opposite direction, ACE2 deficiency upregulated mediators of the RANKL/RANK/OPG axis, a triad that governs osteoclast formation and bone resorption. RANKL binding to RANK on osteoclast precursors drives the differentiation of bone-resorbing cells, while OPG acts as a soluble decoy receptor that restrains the process. Dysregulation of this axis tilts bone turnover toward net loss. Intriguingly, the same axis operates in the brain, where it has been identified as a critical inflammatory signaling system in ischemic injury, and Rho GTPases downstream of these pathways modulate osteoclast differentiation directly. The coordinated shift of this inflammatory skeletal axis in both brain and bone tissue under ACE2 deficiency is one of the study’s most suggestive observations, hinting at a common pathological language spoken by the two organs.

To move from candidate pathways to gene-level targets, the team turned to transcriptomics. They mined public GEO datasets and applied weighted gene co-expression network analysis, or WGCNA, a computational method that groups genes into modules based on correlated expression patterns and identifies the hub genes most central to disease-associated modules. This analysis pinpointed ten hub genes, including DNM1, which encodes dynamin 1, a protein essential for synaptic vesicle recycling; OCRL, a phosphatidylinositol phosphate phosphatase linked to the oculocerebrorenal syndrome; and OPA1, a mitochondrial fusion protein whose mutations cause dominant optic atrophy and which has been implicated in mitochondrial parkinsonism through stem cell modeling. The dysregulation of these genes was linked to synaptic dysfunction and inflammation—two processes squarely at the heart of Parkinson’s pathophysiology.

The team then evaluated whether these hub genes could serve as diagnostic biomarkers. Using receiver operating characteristic, or ROC, analysis on public single-disease transcriptome datasets for Parkinson’s disease and osteoporosis separately, they found that the core gene signatures achieved areas under the curve ranging from 0.683 to 0.981, indicating diagnostic accuracy that spans moderate to near-perfect discrimination. Functional enrichment of the core genes pointed to involvement in synaptic signaling, MAPK signaling, and the Rap1 and Ras pathways—small GTPase cascades that regulate cell proliferation, differentiation, and cytoskeletal dynamics in both neurons and bone cells. Such dual-diagnostic performance, if replicated in human cohorts, would suggest that a shared molecular signature underlies both conditions and could be exploited clinically to identify patients at risk of combined neurodegenerative and skeletal decline.

The authors are appropriately measured in their claims. They emphasize that these are preclinical findings obtained under short-term MPTP treatment in growing young male mice, meaning that the observed bone metabolic disturbance was transient and that the results may not translate directly to elderly human patients, in whom Parkinson’s disease typically manifests and in whom bone loss is chronic and sex-dependent. They also stress that the coordinated dysregulation observed in brain and bone is consistent with a bone-brain axis pathological phenotype, but that the current experimental design cannot confirm causal bidirectional cross-talk between the tissues. Distinguishing whether ACE2 deficiency independently damages both organs, or whether pathology in one propagates to the other—perhaps through circulating osteocalcin, sympathetic nervous system output, or inflammatory mediators—will require interventional studies that manipulate one tissue and measure the other.

Even with those caveats, the study offers a compelling framework and a set of concrete targets for follow-up. Restoring ACE2 activity or mimicking its product, angiotensin-(1–7), has already shown neuroprotective effects in experimental Parkinson’s models, including reduced α-synuclein expression through the NEAT1/miR-153-3p axis, and ACE2 activation has been reported to promote hippocampal neurogenesis via Wnt/β-catenin signaling. The present results raise the possibility that such therapies could carry a skeletal benefit as well, protecting against the osteoporosis that so often compounds the disability of Parkinson’s disease. The ten hub genes, meanwhile, provide a molecular shortlist for mechanistic validation, and their diagnostic AUC values justify testing in human blood or tissue datasets. As the bone-brain axis matures from a descriptive concept into a mechanistic research program, work like this demonstrates how a single molecule, studied across two organs at once, can illuminate disease connections that medicine has long observed clinically but struggled to explain at the level of genes and signaling pathways.

Subject of Research: ACE2-dependent molecular mechanisms linking Parkinson's disease neurodegeneration and bone metabolic alterations via the bone-brain axis

Article Title: ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis

Article References: Liu, T., Ren, Y., Tian, X., & Wei, J. (2026). ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis. Molecular Genetics and Genomics, 301(1), Article 185. https://doi.org/10.1007/s00438-026-02511-2

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02511-2

Keywords: Parkinson's disease, ACE2, bone metabolism, bone-brain axis, osteoporosis, Wnt/beta-catenin signaling, RANKL/RANK/OPG, IGF-1, hub genes, WGCNA, alpha-synuclein, MPTP mouse model